Antibiotic Early Endpoints: FDA Looking At Patient Observations
This article was originally published in RPM Report
Executive Summary
An effort to identify early biomarkers of antibiotic efficacy is turning toward patient assessments of drug activity. FDA and industry scientists are both participating in the biomarker effort. The attention to patient observations reflects a growing interest at FDA.